Aristeia Capital’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Aristeia Capital’s Portfolio DMAA Stock Details DMAA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.73M	Sell	350,000 -531,716	-60%	-$5.63M	0.05%	215
2026 Q1	$9.24M	Hold	881,716	–	–	0.19%	100
2025 Q4	$9.15M	Hold	881,716	–	–	0.2%	74
2025 Q3	$9.06M	Hold	881,716	–	–	0.21%	69
2025 Q2	$8.99M	Sell	881,716 -18,284	-2%	-$185K	0.24%	65
2025 Q1	$9.02M	Buy	+900,000	New	+$9M	0.23%	59

Other funds holding DMAA

Karpus Investment Management Pittsford, New York $3.34B AUM 3.39% 1-Year Est. Return

Mizuho Securities USA New York $6.3B AUM 30.7% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $14.9B AUM 3.61% 1-Year Est. Return

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

First Trust Capital Management Chicago, Illinois $2.08B AUM 59.2% 1-Year Est. Return

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 22.91% 1-Year Est. Return

SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return

Aristeia Capital's DMAA Position: Q2 2026 in Review

Aristeia Capital reduced its Drugs Made In America Acquisition Corp (DMAA) stake by 60% in Q2 2026, selling an estimated $5.63M and leaving 350,000 shares worth $3.73M. The position accounts for 0.05% of the portfolio, ranked #215.

Aristeia Capital first reported a position in DMAA in Q1 2025 and has held it in 6 quarters since. The position peaked at $9.24M in Q1 2026. 23 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

Aristeia Capital held 350,000 shares of Drugs Made In America Acquisition Corp worth $3.73M as of Q2 2026.
Aristeia Capital sold 531,716 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $5.63M.
Drugs Made In America Acquisition Corp made up 0.05% of Aristeia Capital's portfolio in Q2 2026, its #215 holding.
Aristeia Capital first reported a position in Drugs Made In America Acquisition Corp in Q1 2025 and has held it in 6 quarters since.
Aristeia Capital's Drugs Made In America Acquisition Corp position peaked at $9.24M in Q1 2026.
23 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Aristeia Capital's 13F filing for Q2 2026, filed 14 Aug 2026.